Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances
Jiahui Zhang,Jingyi Fan,Mariusz Skwarczynski,Rachel J Stephenson,Istvan Toth,Waleed M Hussein
DOI: https://doi.org/10.2147/IJN.S269986
IF: 7.033
2022-02-25
International Journal of Nanomedicine
Abstract:Jiahui Zhang, 1, &ast Jingyi Fan, 1, &ast Mariusz Skwarczynski, 1 Rachel J Stephenson, 1 Istvan Toth, 1– 3 Waleed M Hussein 1 1 School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; 2 School of Pharmacy, The University of Queensland, Woolloongabba, QLD, Australia; 3 Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia &astThese authors contributed equally to this work Correspondence: Waleed M Hussein, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia, Tel +61 7 3365 2782, Email Persistent infection with high-risk human papillomaviruses (HPVs), such as HPV-16 and HPV-18, can induce cervical cancer in humans. The disease carries high morbidity and mortality among females worldwide. Inoculation with prophylactic HPV vaccines, such as Gardasil ® or Cervarix ® , is the predominant method of preventing cervical cancer in females 6 to 26 years of age. However, despite the availability of commercial prophylactic HPV vaccines, no therapeutic HPV vaccines to eliminate existing HPV infections have been approved. Peptide-based vaccines, which form one of the most potent vaccine platforms, have been broadly investigated to overcome this shortcoming. Peptide-based vaccines are especially effective in inducing cellular immune responses and eradicating tumor cells when combined with nanoscale adjuvant particles and delivery systems. This review summarizes progress in the development of peptide-based nanovaccines against HPV infection. Keywords: human papillomavirus, cervical cancer, peptide-based vaccines, nanovaccine Cervical cancer is a malignant tumor formed in the stem of the uterus. 1 Human papillomavirus (HPV) is a pathogen that causes fatal cervical cancer and related cancerous diseases; it has been detected in 99.7% of all cervical cancers. 2 Two viral proteins, E6 and E7, are pivotal in triggering infected cells to undergo oncogenesis with uncontrolled proliferation, unrestricted telomerase activity, and subsequently cervical cancer growth. 3 HPV infection can cause cancer in the cervix, but also in the vagina, vulva, penis, and oropharynx. 1 Typically, the cervix comprises squamous cells on the outer layer and columnar gland cells on the inner side. Carcinogenesis mainly occurs at the junction of these two cell types, forming squamous cell carcinoma (>90%) or adenocarcinoma. 4,5 Specifically, the initial infection may cause dysplasia, namely, cervical intraepithelial neoplasia (CIN) or adenocarcinoma, in situ. If the infection persists and cannot be cleared by the body's immune system, it leads to an invasive cancer. 5 The treatment of cervical cancer depends on how developed the cancer is: from cervical carcinoma in situ to stages I–IV. Primary treatments for cervical cancer include surgery, radiation therapy and/or chemotherapy. For early or small-scale carcinoma, surgery and radiation therapy can virtually eradicate cell infection and achieve recovery. For cervical cancer stages IB and IIA, interventional chemotherapy is often required for co-treatment. Commonly used chemotherapy drugs include cisplatin, carboplatin, paclitaxel (Taxol ® ), and topotecan. 5 Unfortunately, radiation and chemotherapy often cause many side effects due to their limited targeting affinity towards tumor cells. Vaccination against HPV infection and cervical cancer offers a promising new treatment option without the risk of significant adverse effects. 6 Traditional vaccines have been based on live-attenuated or killed microorganisms derived from pathogenic viruses or bacteria, which directly trigger the immune system to secrete neutralizing antibodies against pathogenic antigens. 6–8 Importantly, currently available HPV prophylactic subunit vaccines, which induce antibody-based responses, cannot be used for effective cancer eradication. 9,10 Fortunately, new vaccines targeting cellular immune responses are being developed and can be applied for cancer treatment. 10–12 However, the use of cancer cell homogenates or cancer-associated proteins is associated with a risk of inducing autoimmune responses. Therefore, peptide-based antigens are being extensively assessed in cancer vaccine designs: several of these vaccines have reached Phase III clinical trials. 13,14 As an effective vaccine candidate platform, peptide-based vaccines have the potential to induce cellular immune responses and eliminate cervical cancer using non-autoimmunogenic antigen sequences derived from cancer-associated proteins. Peptide-based -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology